The European Medicines Agency (EMA) has initiated real-time review of data on the oral antiviral drug molnupiravir developed by Merck Sharp & Dohme, in collaboration with Ridgeback Biotherapeutics for the treatment of Covid-19 in adults.
This was announced by the EMA.
According to the first results of the trials, the drug can prevent hospitalization or death in patients.
If marketing authorization is granted by the European Commission, the companies say, Molnupiravir could be the first antiviral pill to treat COVID-19 in the European Union.
